Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: ...
The active substance in Zilbrysq, zilucoplan, is designed to attach to the C5 complement protein, which is part of the immune system called the ‘complement system’. Myasthenia gravis is caused by the production of autoantibodies (proteins that attack parts …